Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
1321 Riboflavine 3 mg Tablet A11HA04000T1001XX C For prevention and treatment of riboflavine deficiency CHILD: 2.5-10 mg/day in divided doses. ADULT: 5-30 mg/day in divided doses
1322 Rifampicin 100 mg/5 ml Syrup J04AB02000L9001XX A Tuberculosis and leprosy CHILD: 20 mg/kg body weight daily in 1 - 2 doses. Up to 1 year: 10 mg/kg body weight in a single daily dose
1323 Rifampicin 150 mg Capsule J04AB02000C1001XX B i) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitis i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) 600 mg/day iii) 600 mg twice daily for 2 days
1324 Rifampicin 150 mg, Isoniazid 75 mg, Pyrazinamide 400 mg & Ethambutol HCl 275 mg Tablet J04AM06000T1001XX B Treatment of both pulmonary and extrapulmonary tuberculosis, in the intensive treatment phase ADULT: 30 - 37 kg: 2 tablets daily, 38 - 54 kg: 3 tablets daily, 55 - 70 kg: 4 tablets daily, more than 70 kg: 5 tablets daily
1325 Rifampicin 150mg + Isoniazid 75mg tablet J04AM02000T1001XX B For pulmonary tuberculosis in which organisms are susceptible in continuation phase treatment for 4 months 30-37kg: 2 tablets once daily, 38-54kg: 3 tablets once daily, 55-70kg: 4 tablets once daily, Above 70kg: 5 tabs once daily
1326 Rifampicin 300 mg Capsule J04AB02000C1002XX B i) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitis i) Tuberculosis ADULT: Daily doses: 10mg/kg/day Body weight doses: 10-15/kg/day CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Maximum daily dose : 600mg Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) Leprosy: ADULT: 600 mg/day CHILDREN: 10mg/kg iii) Prophylaxis for meningococcal meningitis: ADULT: 600 mg twice daily for 2 days CHILDREN: 10mg/kg twice daily for 2 days INFANT: 5mg/kg twice daily for 2 days"
1327 Rifampicin, Dapsone & Clofazimine J04AM02961T9901XX B For the treatment of leprosy and tuberculosis Rifampicin: 600 mg once monthly, Dapsone: 100 mg daily, Clofazimine: 300 mg once monthly and 50 mg daily (or 100 mg on alternate days)
1328 Ringers Solution (contained sodium chloride, potassium chloride and calcium chloride) B05XA30905P6001XX B As a source of electrolytes and water for hydration/replenishing of chloride According to the needs of the patient
1329 Risperidone 1 mg Tablet N05AX08000T1001XX B i) Schizophrenia, including first episode psychosis, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions ii) Short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation. i) ADULT: Initial dose: 2 mg/day. Maintenance dose: 4 to 6 mg. Max: 16mg/day CHILD: Not recommended ELDERLY: Initial dose: 0.5 mg twice daily. Maintenance: 1 to 2 mg twice daily. ii) CHILD & ADOLESCENTS, 5-18 years ≥ 50 kg: Initial - 0.5 mg once daily Optimum dose: 1mg once daily < 50 kg: Initial - 0.25 mg once daily Optimum dose: 0.5mg once daily Dosing should be individualized according to product insert.
1330 Risperidone 1 mg/ml Oral Solution N05AX08000L5001XX A i) Schizophrenia, including first episode psychosis, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions ii) Short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation. i) ADULT: Initial dose: 2 mg/day. Maintenance dose: 4 to 6 mg. Max: 16mg/day CHILD: Not recommended ELDERLY: Initial dose: 0.5 mg twice daily. Maintenance: 1 to 2 mg twice daily. ii) CHILD & ADOLESCENTS, 5-18 years ≥ 50 kg: Initial - 0.5 mg once daily Optimum dose: 1mg once daily < 50 kg: Initial - 0.25 mg once daily Optimum dose: 0.5mg once daily Dosing should be individualized according to product insert.
1331 Risperidone 2 mg Tablet N05AX08000T1002XX B Schizophrenia ADULT: Initial dose: 2 mg/day. Maintenance dose: 4 to 6 mg. Max: 16mg/day CHILD: Not recommended ELDERLY: Initial dose: 0.5 mg twice daily. Maintenance: 1 to 2 mg twice daily. Dosing should be individualized according to product insert.
1332 Risperidone 25 mg Injection (Long Acting) N05AX08000P3001XX A* Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia 25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1333 Risperidone 37.5 mg Injection (Long Acting) N05AX08000P3002XX A* Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia 25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1334 Risperidone 50 mg Injection (Long Acting) N05AX08000P3003XX A* Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia 25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1335 Ritonavir 100 mg Capsule J05AE03000C1001XX A* Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells or c) Viral load more than 10,000 copies/ml ADULT: (Single PI) initially 300 mg twice daily, increase by 100 mg twice daily increments to 600 mg twice daily. (Dual PI) Initially 200mg BD, then increase by 100mg BD & reaching 400mg BD within 2 wk.
1336 Ritonavir 80 mg/ml Solution J05AE03000L9901XX A* Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells or c) Viral load more than 10,000 copies/ml ADULT: 400 - 600 mg twice daily. CHILD: >1 month, initiate at dise of 25mg/m2 twice daily, titrate dose upward every 2-3 days by 50mg/m2 twice daily (maximum dose 600mg twice daily)
1337 Rituximab 10mg/ml Injection L01XC02000P3001XX A* i) Treatment of patients with relapsed or chemo-resistant low grade or follicular B-cell Non-Hodgkin's lymphoma ii) Adjunctive therapy with combination chemoagents for aggressive Non-Hodgkin Lymphoma iii) Severe active rheumatoid arthritis with inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARDs) including one or more tumour necrosis factor (TNF) inhibitor therapies iv) Maintenance in relapsed/ refractory follicular lymphoma after response to induction therapy i) 375 mg/m2 BSA administered as an IV infusion through a dedicated line once weekly for 4 weeks ii) Combination with CHOP (cyclophosphamide, doxorubicin, prednisone and vincristine) as 375 mg/m2 BSA on day 1 of each chemotherapy cycle for 8 cycles after IV administration of the glucocorticoid component of CHOP. iii) 1000 mg IV infusion followed by a second 1000 mg IV infusion two weeks later iv) 375mg/m2 BSA once every 3 months until disease progression or for a maximum period of two years.
1338 Rituximab 1400mg/11.7ml solution for subcutaneous injection L01XC02-000-P30-04-XXX A* i) Treatment of patients with relapsed or chemo-resistant low grade or follicular B-cell Non-Hodgkin's lymphoma; ii) Adjunctive therapy with combination chemo-agents for aggressive Non-Hodgkin Lymphoma; iii) Maintenance in relapsed/ refractory follicular lymphoma after response to induction therapy. i) As monotherapy, first cycle with rituximab (IV formulation) 375mg/m2 administered as an intravenous infusion, followed by subsequent cycles with rituximab SC at a fixed dose of 1400mg per cycle, once weekly. In total: 4 weeks. ii) Combination with CHOP (cyclophosphamide, doxorubicin, prednisone and vincristine): first dose with rituximab (IV formulation) 375 mg/m2 administered as an intravenous infusion followed by subsequent cycles with rituximab SC injected at a fixed dose of 1400mg per cycle. In total: for up to 8 cycles. Rituximab should be administered on day 1 of each chemotherapy cycle after IV administration of the glucocorticoid component of CHOP. iii) 1400mg SC once every 3 months until disease progression or for a maximum period of two years. Note: • Premedication consisting of an anti-pyretic, antihistamine (e.g. paracetamol and diphenhydramine) and glucocorticoids, before each administration of rituximab. • All patients must always receive their first dose of rituximab by intravenous administration (using intravenous formulation) at a dose of 375mg/m2 body surface area. The subcutaneous formulation of 1400mg should only be given at the second or subsequent cycles. • Patients who were not able to receive the full rituximab intravenous infusion dose should continue to receive subsequent cycles with rituximab IV doses. • Subcutaneous formulation is not intended for intravenous administration and should be given via subcutaneous injection only. The 1400 mg strength is intended for subcutaneous use in non-Hodgkin lymphoma (NHL) only.
1339 Rivaroxaban 10 mg Tablet B01AX06000T1001XX A* Prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery 10 mg once daily. Initial dose should be taken 6 to 10 hour post-surgery provided that haemostasis has been established. Duration of treatment: Major hip surgery 5 weeks. Major knee surgery 2 weeks
1340 Rivaroxaban 15 mg Tablet B01AX06000T1002XX A* i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack. ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults. i)20mg once daily or 15mg once daily (for patients with moderate renal impairment (creatinine clearance 30-49 ml/min) ii) & (iii) 15mg BD for 21 days, followed by 20mg OD.
1341 Rivaroxaban 20 mg Tablet B01AX06000T1003XX A* i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack. ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults. i)20mg once daily or 15mg once daily (for patients with moderate renal impairment (creatinine clearance 30-49 ml/min) ii) & iii)15mg BD for 21 days, followed by 20mg OD.
1342 Rivastigmine 1.5 mg Capsule N06DA03123C1001XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1343 Rivastigmine 13.3mg/24hr Transdermal Patch N03DA03123M7003XX A* i) Mild to moderately severe dementia of the Alzheimer's type ii) Severe dementia of the Alzheimer's type iii) Mild to moderately severe dementia associated with Parkinson's disease Use as second line/alternative option if the first line medication with oral tablet failed or patients are not able to tolerate the oral medication. Initial: 4.6mg/24hr once daily Maintenance: 9.5mg/24hr once daily after a minimum of 4 weeks and then 13.3mg/24hr if tolerated Dosing is individualised and according to product insert.
1344 Rivastigmine 2 mg/ml Oral Solution N06DA03123L9901XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily. May be increased after a minimum of 2 weeks of treatment to 3 mg 2 times daily. Subsequently to 4.5 mg 2 times daily, up to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1345 Rivastigmine 3 mg Capsule N06DA03123C1002XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1346 Rivastigmine 4.5 mg Capsule N06DA03123C1003XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1347 Rivastigmine 4.6mg/24hr Transdermal Patch N06DA03123M7001XX A* i) Mild to moderately severe dementia of the Alzheimer's type ii) Severe dementia of the Alzheimer's type iii) Mild to moderately severe dementia associated with Parkinson's disease Use as second line/alternative option if the first line medication with oral tablet failed or patients are not able to tolerate the oral medication Initial: 4.6mg/24hr once daily Maintenance: 9.5mg/24hr once daily after a minimum of 4 weeks and then 13.3mg/24hr if tolerated Dosing is individualised and according to product insert.
1348 Rivastigmine 6 mg Capsule N06DA03123C1004XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1349 Rivastigmine 9.5 mg/24hr Transdermal Patch N06DA03123M7002XX A* i) Mild to moderately severe dementia of the Alzheimer's type ii) Severe dementia of the Alzheimer's type iii) Mild to moderately severe dementia associated with Parkinson's disease Use as second line/alternative option if the first line medication with oral tablet failed or patients are not able to tolerate the oral medication Initial: 4.6mg/24hr once daily Maintenance: 9.5mg/24hr once daily after a minimum of 4 weeks and then 13.3mg/24hr if tolerated Dosing is individualised and according to product insert.
1350 Rocuronium Bromide 10 mg/ml Injection M03AC09320P3001XX A* As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation in adults, children and infants from one month of age. Adult: Initially, 600 mcg/kg by inj. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesthesia. Maintenance: 150 mcg/kg by inj (may reduce to 75-100 mcg/kg if inhalational anaesthesia is used) or by infusion at a rate of 300-600 mcg/kg/hr. Doses should be based on lean body weight for obese patients weighing >30% above the ideal body weight. Child: Infants and children >1 mth: Initially, 600 mcg/kg by inj. Maintenance: 150 mcg/kg by inj or by infusion at a rate of 300-600 mcg/kg/hr, maintenance doses may be required more frequently than in adult patients. Elderly: Reduced maintenance doses: 75-100 mcg/kg. Renal impairment: Initially, 600 mcg/kg by inj. Maintenance: 75-100 mcg/kg. Hepatic impairment: or biliary tract disease: Initially, 600 mcg/kg by inj. Maintenance: 75-100 mcg/kg.

Halaman-halaman